FINNENCE ▪ THE WIRE FILE
THE WIRE · № 58342
News■ Mixed
RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results
KINDNews
DIRECTION■ Mixed
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-09-30 20:05 UTC
LAST UPDATE2026-09-30 20:05 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Portfolio reset to two GI brands changes revenue mix; prior sales figures were under prior owner.
Small-cap strategic reset, unproven economics
CATALYST TO WATCH
Sales trajectory of Rebyota and Clenpiq
MAIN RISK
Narrow product concentration risk
FULL DISPATCH
Executing a full strategic portfolio reset, RedHill is now a stronger commercial entity with Rebyota® and Clenpiq®, two established FDA-approved gastrointestinal (GI) brands that generated $37.5 million in 2025 net sales under Ferring Pharmaceuticals ("Ferring"), an advanced late-stage...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 20262026-09-30 20:05 UTC
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 20262026-09-30 20:05 UTC
→CORRELATIONshares Healthcare
Merger Dominoes Fall as HealthPartners and Essentia Combine2026-09-30 14:11 UTC
Merger Dominoes Fall as HealthPartners and Essentia Combine2026-09-30 14:11 UTC
→CORRELATIONshares Healthcare
Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management2026-09-30 20:30 UTC
Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management2026-09-30 20:30 UTC
←CORRELATIONshares Healthcare
Vasomotor Symptoms Market Poised for Growth Through 2036, Driven by Rising Adoption of Hormonal and Non-Hormonal Therapies2026-09-30 14:31 UTC
Vasomotor Symptoms Market Poised for Growth Through 2036, Driven by Rising Adoption of Hormonal and Non-Hormonal Therapies2026-09-30 14:31 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.